Table 3.
Association of alpha 1-antitrypsin protease inhibitor (PI)-MZ status and standardised lung function adjusted for age, sex, height and height-squared
| Outcome | Cohort | Regression coefficient (95% CI) |
|---|---|---|
| Maximum FEV1 | BO | 0.17 (−0.40 to 0.74) |
| CaPS | 0.09 (−0.12 to 0.30) | |
| ELSA | 0.06 (−0.05 to 0.16) | |
| HAS | 0.11 (−0.34 to 0.56) | |
| HCS | −0.01 (−0.15 to 0.12) | |
| LBC1921 | 0.09 (−0.27 to 0.44) | |
| NSHD | 0.08 (−0.08 to 0.23) | |
| WHII | 0.11 (−0.00 to 0.21) | |
| Combined FE | 0.07* (0.01 to 0.12) | |
| Combined RE | 0.07* (0.01 to 0.12) | |
| Estimated var† | 1.03e−17 (1.80e−32 to 5.87e−03) | |
| Maximum FVC | BO | 0.06 (−0.43 to 0.56) |
| CaPS | 0.13 (−0.08 to 0.34) | |
| ELSA | 0.04 (−0.06 to 0.14) | |
| HAS | 0.35 (−0.04 to 0.74) | |
| HCS | 0.07 (−0.05 to 0.18) | |
| LBC1921 | 0.10 (−0.23 to 0.44) | |
| NSHD | 0.08 (−0.06 to 0.23) | |
| WHII | 0.10 (−0.00 to 0.20) | |
| Combined FE | 0.08** (0.03 to 0.13) | |
| Combined RE | 0.08** (0.03 to 0.13) | |
| Estimated var† | 1.25e−13 (5.20e−27 to 3.01e+00) |
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Estimated variance of the random slope on carrier status modelled by the RE model.
BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of Ageing; FE, fixed effect; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study; LBC1921, Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development; RE, random effect; WHII, Whitehall II Study.